A Neuron-specific Methyl-histone Regulatory Complex
神经元特异性甲基组蛋白调节复合物
基本信息
- 批准号:10615745
- 负责人:
- 金额:$ 48.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AT-Hook MotifsAddressAdoptedAffectAffinityAlternative SplicingBindingBiochemistryBrainCancer cell lineCatalytic DomainCellsCellular biologyChromatinChromatin Remodeling FactorChromatin StructureComplementComplexCryoelectron MicroscopyDNADNA BindingDNA SequenceDataDefectDevelopmentDiseaseEnzymesExcitatory SynapseExonsGene ExpressionGenomic approachGoalsHigher Order Chromatin StructureHistone H3HistonesHumanHuman GeneticsImpairmentIn VitroIntellectual functioning disabilityInvestigationKDM1A geneKnock-outKnowledgeLeadLysineMediatingMediatorMissense MutationModelingMusMutateNeurodevelopmental DisorderNeuronsNucleosomesNucleotidesOrganPHD FingerPathogenesisPathologicPatientsPattern RecognitionPlayProtein IsoformsPublishingRNA SplicingReactionReaderRegulationReportingResearchRoleSpecificitySubstrate SpecificityTestingautism spectrum disordercell typechromatin modificationdemethylationdesignembryonic stem cellexperimental studyfunctional genomicshistone demethylasehistone methylationhistone modificationin vivoinsightinterdisciplinary approachmouse modelneurodevelopmentnovel strategiesprotein protein interactionreconstitutionrecruitstructural biologysynaptogenesistherapeutic targettranscription factortranscriptome
项目摘要
Abstract
It is widely accepted that cell-type-specific gene expression is primarily achieved by cell-type-specific
presence of transcription factors (TFs), which bind to cognate DNA sequences. TFs then initiate changes in
higher-order chromatin structures by recruiting chromatin modifiers, including histone-modifying enzymes.
Unlike TFs, chromatin modifiers tend to be ubiquitously expressed. Among the plethora of chromatin
modifications, regulators of histone methylation are more frequently mutated in neurodevelopmental disorders
(NDDs) such as intellectual disabilities (IDs) and autism. Why is the brain so sensitive to dysregulation of
histone methylation? Is methyl-histone regulation in neurons unique? Investigation of a limited number of cell
types, cancer-cell lines, and embryonic stem cells has hampered our ability to address these questions.
The overarching goal of my research group is to contribute to the understanding of how methyl-histone
regulations underlie normal and pathological brain functions. Our focus is on the LSD1-PHF21A histone-
demethylation complex, which involves neuron-specific alternative splicing. LSD1 is a histone demethylase for
histone H3 lysine 4 (H3K4me). PHF21A was the first-discovered “zero reader,” which recognizes unmethylated
H3K4 (H3K4me0), the reaction product of canonical LSD1 (LSD1-c). Both LSD1 and PHF21A
haploinsufficiencies lead to NDDs, suggesting their importance in brain development. The neuronal LSD1
isoform (LSD1-n), which carries an alternative exon in its catalytic domain, was reported to have distinct
substrate specificity. However, the specific lysine(s) targeted by LSD1-n remains controversial. The goal of this
proposal is to determine the roles of the neuronal LSD1-PHF21A complex. Our preliminary study showed that
PHF21A also carries an alternative exon right upstream of the H3K4me0-recognizing PHD finger. This region
of PHF21A contains an AT-hook motif, which directly binds to DNA; we found that the alternative exon disrupts
the AT-hook, hence the DNA binding, but not H3K4me0 binding. These observations raise an exciting
possibility that the neuronal PHF21A isoform (PHF21A-n) recognizes nucleosomes in a distinct manner
compared to canonical PHF21A (PHF21A-c), thereby cooperating with LSD1-n to generate the neuronal
transcriptome for normal brain development.
We propose testing the hypothesis using multidisciplinary approaches encompassing cell biology,
biochemistry, and structural biology. The research plan was developed to provide both mechanistic insights
into the regulation of histone modifications and a better understanding of the pathogenesis of
neurodevelopment disorders, which could lead to novel approaches for brain-specific therapeutic targets.
摘要
广泛接受的是,细胞类型特异性基因表达主要通过细胞类型特异性表达来实现。
存在与同源DNA序列结合的转录因子(TF)。TF然后启动更改,
高级染色质结构通过招募染色质修饰剂,包括组蛋白修饰酶。
与TF不同,染色质修饰剂倾向于普遍表达。在众多的染色质中
修饰,组蛋白甲基化的调节因子在神经发育障碍中更频繁地突变,
(NDD),如智力残疾(ID)和自闭症。为什么大脑对神经系统的失调如此敏感
组蛋白甲基化?神经元中甲基组蛋白的调节是独特的吗?有限数量细胞的研究
类型、癌细胞系和胚胎干细胞的研究阻碍了我们解决这些问题的能力。
我的研究小组的首要目标是帮助理解甲基组蛋白
调节是正常和病理性脑功能的基础。我们的重点是LSD 1-PHF 21 A组蛋白-
去甲基化复合物,其涉及神经元特异性选择性剪接。LSD 1是一种组蛋白脱甲基酶,
组蛋白H3赖氨酸4(H3 K4 me)。PHF 21 A是第一个发现的“零阅读器”,它识别未甲基化的
H3 K4(H3 K4 me 0),典型LSD 1(LSD 1-c)的反应产物。LSD 1和PHF 21 A
haploinflammencies导致NDD,这表明它们在大脑发育中的重要性。神经元LSD 1
在其催化结构域中携带选择性外显子的同种型(LSD 1-n),据报道具有明显的
底物特异性然而,LSD 1-n靶向的特异性赖氨酸仍然存在争议。这个目标
该研究旨在确定神经元LSD 1-PHF 21 A复合物的作用。我们的初步研究表明,
PHF 21 A还携带H3 K4 me 0识别PHD指上游的选择性外显子。这一地区
的PHF 21 A包含一个AT钩基序,它直接结合到DNA;我们发现,选择性外显子破坏了
AT-钩,因此DNA结合,但不H3 K4 me 0结合。这些观察提出了一个令人兴奋的
神经元PHF 21 A亚型(PHF 21 A-n)以不同方式识别核小体的可能性
与典型的PHF 21 A(PHF 21 A-c)相比,从而与LSD 1-n合作产生神经元
正常大脑发育的转录组。
我们建议使用包括细胞生物学在内的多学科方法来测试这一假设,
生物化学和结构生物学。该研究计划的制定提供了两个机制的见解
组蛋白修饰的调节和更好地理解的发病机制,
神经发育障碍,这可能导致大脑特异性治疗靶点的新方法。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Batch Production of High-Quality Graphene Grids for Cryo-EM: Cryo-EM Structure of Methylococcus capsulatus Soluble Methane Monooxygenase Hydroxylase.
- DOI:10.1021/acsnano.3c00463
- 发表时间:2023-03-28
- 期刊:
- 影响因子:17.1
- 作者:Ahn, Eungjin;Kim, Byungchul;Park, Soyoung;Erwin, Amanda L.;Sung, Suk Hyun;Hovden, Robert;Mosalaganti, Shyamal;Cho, Uhn-Soo
- 通讯作者:Cho, Uhn-Soo
A neuron-specific microexon ablates the novel DNA-binding function of a histone H3K4me0 reader PHF21A.
神经元特异性微外显子消除了组蛋白 H3K4me0 阅读器 PHF21A 的新型 DNA 结合功能。
- DOI:10.1101/2023.10.20.563357
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Porter,RobertS;Nagai,Masayoshi;An,Sojin;Gavilan,MariaC;Murata-Nakamura,Yumie;Bonefas,KatherineM;Zhou,Bo;Dionne,Olivier;Manuel,JeruManoj;St-Germain,Joannie;Browning,Liam;Laurent,Benoit;Cho,Uhn-Soo;Iwase,Shigeki
- 通讯作者:Iwase,Shigeki
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shigeki Iwase其他文献
Shigeki Iwase的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shigeki Iwase', 18)}}的其他基金
Diurnal Experimental Models to Investigate Neural Mechanisms of Sleep Disturbance in Smith-Magenis Syndrome
研究史密斯-马吉尼斯综合征睡眠障碍神经机制的昼夜实验模型
- 批准号:
10359869 - 财政年份:2021
- 资助金额:
$ 48.22万 - 项目类别:
A Neuron-specific Methyl-histone Regulatory Complex
神经元特异性甲基组蛋白调节复合物
- 批准号:
10401853 - 财政年份:2020
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopmental disorders
中和神经发育障碍中的表观基因组
- 批准号:
9266842 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopmental disorders
中和神经发育障碍中的表观基因组
- 批准号:
9085410 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopmental disorders
中和神经发育障碍中的表观基因组
- 批准号:
8964042 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
Neutralizing epigenomes in neurodevelopment disorders
中和神经发育障碍中的表观基因组
- 批准号:
9233642 - 财政年份:2015
- 资助金额:
$ 48.22万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.22万 - 项目类别:
Research Grant